HOOK News and Press, HOOKIPA Pharma Inc. From 11/12/20

HOOKIPA Pharma (HOOK): Q3 GAAP EPS of -$0.53 misses by $0.09.Revenue of $4.04M (+98.0% Y/Y) misses by $0.58M.Press Release For further details see: HOOKIPA Pharma EPS misses by $0.09, misses on revenue

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended S...

NEW YORK and VIENNA, Austria, Nov. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will partic...

NEW YORK and VIENNA, Austria, Nov. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release financial results for the th...

- HB-202/HB-201 alternating two-vector therapy is added as an additional arm that expands the ongoing HB-201 clinical trial - Pre-clinical data show that adding an additional arenaviral vector to achieve alternating two-vector therapy enhances immune response NEW YORK and VIENNA, Au...

NEW YORK and VIENNA, Austria, Oct. 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Professor Jea...

Volatility watch: Short interest has been in an uptrend for Vale (NYSE: VALE ) and Barrick Gold (NYSE: GOLD ) , while Tootsie Roll Industries (NYSE: TR ) and Signet Jewelers (NYSE: SIG ) stand out on the list of stocks with the highest percentage of short interest as total float. M...

Peer reviewed article in OncoImmunology demonstrates promising preclinical results for the novel cancer therapy targeting Human Papillomavirus 16 (HPV16) E6/E7  HPV is estimated to cause approximately 5% of the worldwide cancer burden NEW YORK and VIENNA, Austria, Sept. 16, 2020 ...

NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that H...

NEW YORK and VIENNA, Austria, Sept. 09, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that H...